Modelling of the concentration-effect relationship of THC on central nervous system parameters and heart rate - insight into its mechanisms of action and a tool for clinical research and development of cannabinoids

被引:60
作者
Strougo, A.
Zuurman, L. [1 ]
Roy, C. [2 ]
Pinquier, J. L. [2 ]
van Gerven, J. M. A. [1 ]
Cohen, A. F. [1 ]
Schoemaker, R. C.
机构
[1] Pharmacol CNS, Ctr Human Drug Res, NL-2333 CL Leiden, Netherlands
[2] Sanofi Aventis, Rech Dev, Paris, France
关键词
THC; 11-OH-THC; 11-nor-9-COOH-THC; metabolites; NONMEM; nonlinear mixed effect modelling; visual analogue scale; heart rate; body sway;
D O I
10.1177/0269881108089870
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Pharmacokinetics after pulmonary administration of delta-9-tetrahydrocannabinol (THC) and its major metabolites 11-OH-THC and 11-nor-9-COOH-THC was quantified. Additionally, the relationship between THC and its effects on heart rate, body sway and several visual analogue scales was investigated using pharmacokinetic-pharmacodynamic (PK-PD) modelling. This provided insights useful for the research and development of novel cannabinoids and the physiology and pharmacology of cannabinoid systems. First, the PK-PD model gave information reflecting various aspects of cannabinoid systems. The delay between THC concentration and effect was quantified in equilibration half-lives of 7.68 min for heart rate and from 39.2 to 84.8 min for the CNS responses. This suggests that the effect of THC on the different responses could be due to different sites of action or different physiological mechanisms. Differences in the shape of the concentration-effect relationship could indicate various underlying mechanisms. Second, the PK-PD model can be used for prediction of THC concentration and effect profiles. It is illustrated how this can be used to optimise studies with entirely different trial designs. Third, many new cannabinoid agonists and antagonists are in development. PK-PD models for THC can be used as a reference for new agonists or as tools to quantitate the pharmacological properties of cannabinoid antagonists.
引用
收藏
页码:717 / 726
页数:10
相关论文
共 36 条
[1]   The effects of cannabinoids on the brain [J].
Ameri, A .
PROGRESS IN NEUROBIOLOGY, 1999, 58 (04) :315-348
[2]   KINETIC-STUDY OF SMOKING MARIJUANA [J].
BARNETT, G ;
CHIANG, CWN ;
PEREZREYES, M ;
OWENS, SM .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1982, 10 (05) :495-506
[3]  
BEAL SL, 1982, CRIT REV BIOMED ENG, V8, P195
[4]   USE OF ANALOG SCALES IN RATING SUBJECTIVE FEELINGS [J].
BOND, A ;
LADER, M .
BRITISH JOURNAL OF MEDICAL PSYCHOLOGY, 1974, 47 (SEP) :211-218
[5]   Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle [J].
Bonz, A ;
Laser, M ;
Küllmer, S ;
Kniesch, S ;
Babin-Ebell, J ;
Popp, V ;
Ertl, G ;
Wagner, JA .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 41 (04) :657-664
[6]   Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development - The 'Wooden Shoe' paradigm [J].
Breimer, DD ;
Danhof, M .
CLINICAL PHARMACOKINETICS, 1997, 32 (04) :259-267
[7]  
Chiang C N, 1987, NIDA Res Monogr, V79, P173
[8]   MARIJUANA EFFECT AND DELTA-9-TETRAHYDROCANNABINOL PLASMA-LEVEL [J].
CHIANG, CN ;
BARNETT, G .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 36 (02) :234-238
[9]  
Ebert U, 1998, EUR J CLIN INVEST, V28, P944
[10]   SIMULTANEOUS MODELING OF PHARMACOKINETICS AND PHARMACODYNAMICS WITH A NONPARAMETRIC PHARMACODYNAMIC MODEL [J].
FUSEAU, E ;
SHEINER, LB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (06) :733-741